Related Experiment Videos
Increased pertechnegas lung clearance in interstitial lung disease
B Mouratidis1, J Lising, S Nogrady
1Department of Nuclear Medicine, The Canberra Hospital, Garran, ACT, Australia.
Clinical Nuclear Medicine
|February 13, 1999
Summary
Pertechnegas, a lung imaging agent, shows faster clearance in interstitial lung disease (ILD) patients. This method, especially with chest X-rays, is highly effective for diagnosing active ILD.
Area of Science:
- Pulmonary Medicine
- Radiology
- Nuclear Medicine
Background:
- Interstitial lung disease (ILD) involves lung inflammation and increased membrane permeability.
- Diagnosis relies on clinical assessment, imaging (CT, X-ray), lung function tests, and biopsy.
- Radionuclide tracers like Tc-99m DTPA indicate increased lung clearance in ILD.
Purpose of the Study:
- To evaluate the clearance rate of pertechnegas, a modified microaerosol agent, for assessing interstitial lung disease (ILD).
- To determine the diagnostic accuracy of pertechnegas in differentiating ILD from non-ILD conditions.
Main Methods:
- Thirty-two patients (22 ILD, 10 non-ILD) underwent pertechnegas lung imaging.
- Pertechnegas, an aerosol agent, was administered, and lung clearance rates were measured.
- Clearance rates were calculated using exponential fitting on regions of interest.
Main Results:
- Mean pertechnegas clearance time was significantly faster in ILD patients (5.78 min) compared to non-ILD (8.53 min) (P < 0.001).
- Pertechnegas clearance showed 90% sensitivity and 60% specificity for ILD.
- Combining pertechnegas with chest roentgenography improved diagnostic accuracy to 100% sensitivity and 90% specificity.
Conclusions:
- Pertechnegas is a highly effective tool for detecting active interstitial lung disease (ILD).
- It accurately differentiates between active ILD and non-ILD conditions.
- The combination of pertechnegas and chest roentgenography offers high diagnostic performance for ILD.